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S U M M A R Y
Background: Lymphadenitis is one of the presenting signs of toxoplasmosis. Co-trimoxazole (CTM) has a
good therapeutic effect on ocular and cerebral infections caused by Toxoplasma gondii. Since this
infection is endemic in Ahvaz and because of the lack of investigations into the therapeutic effects of CTM
in toxoplasmic lymphadenitis (TL), this study was performed from 2005 to 2007 to determine the
therapeutic effects of CTM on TL in Ahvaz.
Methods: Forty-six patients with TL were enrolled in this randomized, double-blind, placebo-controlled
trial study. Diagnosis was based on clinical examination, serological tests (chemiluminescent), and
histopathological examinations. Palpable lymph nodes, IgM >8 IU, and follicular hyperplasia were
deﬁned as positive ﬁndings. Patients were randomly assigned to the comparison groups (23 patients in
each group). The CTMpatients were treatedwith 48 mg/kg/day CTMdivided into two doses, for 1month.
The placebo patients were treated with placebo for 1 month. The primary endpoint for treatment
response was 1month. Follow-up with physical and serological examinations occurred at 6months. The
secondary endpoint was at 6 months. Clinical response was deﬁned as no palpable lymph nodes and
serological response as IgM <6 IU; a patient was cured if the lymph nodes were no longer palpable and
IgM was <6 IU. Results were analyzed using SPSS software and the Chi-square test.
Results: At the end of treatment, a clinical responsewas observed in 15 (65.2%) in the CTM group and ﬁve
(21.7%) in the placebo group. A serological response was seen in 65.2% of the CTM group and 13.0% of the
placebo group. The cure rate was 65.2% in the CTM group and 13.1% in the placebo group. There was a
signiﬁcant difference in therapeutic effect between the two groups (52.2%, 95% conﬁdence interval 32.1–
72%, p < 0.001). There was no difference in the site of infection between the two groups (p > 0.05).
Conclusion: CTM has a good therapeutic effect in TL and may be used in selected patients for whom
treatment is required.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Lymphadenitis is an acute or chronic inﬂammation of the
lymph nodes.1 Treatment is dependent on the nature of the
infecting organism, host defense, and the location of the inﬂamed
lymph node.1 Toxoplasmic lymphadenitis (TL) is prevalent in areas
where Toxoplasma gondii infection is endemic, such as Iran.2
Diagnosis of TL in the immunocompetent patient is based
primarily on serological testing, although sometimes a node
biopsy is performed because of initial concerns for lymphoma.3–9
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best of our knowledge there is no recommended antibiotic
treatment for TL in immunocompetent individuals from previous
studies or in the literature.3 Therefore, because of our experience of
the frequent presentation of patients with TL and their persistent
requests for treatment, we investigated the therapeutic effects of
co-trimoxazole (CTM) on TL by comparing the clinical and
laboratory effects of CTM and placebo in a double-blind,
randomized trial.
2. Patients and methods
All patients with a clinical presentation of enlarged lymph
nodes at the Infectious Diseases Clinic were candidates for
inclusion in the study. They were not entered into the study ifses. Published by Elsevier Ltd. All rights reserved.
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tivity/intolerance to sulfonamides or trimethoprim antibiotics, (2)
the presence of another infectious disease or a febrile illness, (3)
any other condition affecting drug absorption or immunity, (4)
they had received any other antibiotic within the 30 days prior to
study enrolment.
This study was performed from 2005 to 2007 at an outpatient
infectious disease clinic in Ahvaz, a city in the southwest of Iran. The
clinical diagnosis was conﬁrmed by serological and histopatholog-
ical examination.Male or female (unless breastfeeding or pregnant)
patients were eligible to enter the study. Written informed consent
was obtained from all patients. The study was approved by the
infectious disease ethics committee of a training hospital.
A total of 46 patients were randomized to the two treatment
groups using a double-blind, double-dummy technique. Twenty-
three (15 male, eight female) patients were treated for 1 month
with CTM at a dose of 40 mg sulfamethoxazole/8 mg trimethoprim
per kg body weight, twice daily, and 23 (17 male, six female)
patients were treated with placebo tablets, which were visually
identical to the tested drug. The sample size of the studywas based
on the number of referred patients rather than by statistical
formula. A ﬂow diagram of the trial is shown in Figure 1. The
diagram shows the number of patients actively followed up at
different stages of the trial.
Criteria for determining the presence of TLwere palpable lymph
nodes, IgM >8 IU, and follicular hyperplasia. Serological examina-
tion was performed by chemiluminescent method using the
Liaison kit (DiaSorin, Saluggia, Italy), which has a sensitivity of
100% and speciﬁcity of 96%. The primary study endpoint was at 1
month and the secondary endpoint at 6 months.
Patient response to treatment was monitored by assessing
clinical and laboratory ﬁndings at baseline and at months 1 and 6.
Response to treatment was classiﬁed as satisfactory or unsatisfac-
tory as follows: satisfactory – a patient was cured if the lymph
nodes were no longer palpable and IgM was <6 IU; unsatisfactory
– failure of therapy with no apparent clinical or laboratory
improvement. Data were analyzed using SPSS software forFigure 1. Flow diagram of the trial of co-trimoxazole for the treatment of
toxoplasmic lymphadenitis.Windows (SPSS Inc., Chicago, IL, USA). The two treatment groups
were compared using a Chi-square test for the location of lymph
nodes. Fisher’s exact test was used to compare the two groups for
their response to treatment. The CONSORT guidelines were used
for reporting the results.14
3. Results
Of the total 46 patients, 14 (30.4%) were female. The mean age
of the male patients was 13.0  7.8 years and of female patients was
13.2  7.1 years. Patient demographic characteristics and locations of
the lymph nodes are shown in Table 1.
At the end of treatment (primary endpoint), a clinical response
was observed in 15 (65.2%) in the CTMgroup and ﬁve (21.7%) in the
placebo group. A serological responsewas seen in 65.2% of the CTM
group and 13.0% of the placebo group. The 1-month primary
endpoint cure rate in the CTM group was 65.2% and in the placebo
group was 13.0% (Table 2). There was a signiﬁcant difference in
therapeutic effect between the two groups (52.2%, 95% conﬁdence
interval 32.1–72%; p < 0.001). Therewas no difference in the site of
infection between the two groups (p > 0.05). The secondary
endpoint cure rates (at 6 months) are also shown in Table 2.
4. Discussion
The present study showed that CTM has an acceptable
therapeutic effect on TL. The cure rate in the CTM group was
signiﬁcantly higher than in the placebo group (65.2% vs.13.1%).
Although, to date there has been no study published on the effects
of CTM in TL, studies on the therapeutic effect of this drug on
Toxoplasma infections of the brain and eye have been clearly
described.10–13 As a result of the clinical and serological responses
to CTM and because of the good availability and cost-effectiveness
of this drug, we recommend CTM as an alternative drug for the
treatment of TL where it is indicated.
TL is usually a chronic disease and without treatment lasts for 6
months or more.2 Because of anxiety due to the prolonged
enlargement of the lymph nodes, parents of children with TL (the
most prevalent age group) demand antibiotics for this disease. The
administration of unnecessary antibiotics by general physicians
and self-administration result in a high level of antibiotic
consumption in the study region, an area where antibiotic-Table 1
Patient demographic characteristics and location of the affected lymph nodes
Variable Co-trimoxazole
group, n (%)
Placebo
group, n (%)
Age (years) <15 15 (65.2) 17 (73.9)
15–25 6 (26.1) 4 (17.4)
>25 2 (8.7) 2 (8.7)
Gender Male 15 (65.2) 17 (73.9)
Female 8 (34.8) 6 (26.1)
Site of lymph node Neck 19 (82.6) 16 (69.6)
Submental 3 (13.0) 4 (17.4)
Axillary 1 (4.4) 3 (13.0)
Table 2
Treatment response in the patients with toxoplasmic lymphadenitis
End point CTM group
(n=23), n (%)
Placebo group
(n=23), n (%)
Difference
(95% CI), %
p-Value
Primary endpoint:
Cured 15 (65.2) 3 (13.1) 52.2 (32.1–72) <0.001
Secondary endpoint:
Cured 20 (87.0) 10 (43.5) 46.4 (24.6–64) 0.002
CTM, co-trimoxazole; CI, conﬁdence interval. (p<0.05 is signiﬁcant.).
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results of this study could help us to limit the duration of disease to
1 month and prevent a longer duration of antibiotic use.
There were some limitations to this study, such as the small
sample size, the restriction of the study to an infectious disease
clinic, and the lack of comparison of CTMwith the ﬁrst choice anti-
Toxoplasma drug (i.e., sulfadiazine/pyrimethamine).
In conclusion, CTM has a good therapeutic effect on TL andmay
be used in selected patients for whom treatment is required. We
recommend: (1) large-scale multicenter clinical trial studies in the
future, (2) a comparative study with CTM and sulfadiazine/
pyrimethamine.
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